Fulcrum Asset Management’s Procept Biorobotics PRCT Stock Holding History

Fulcrum Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.39K	Buy	+106	New	+$2.65K	﹤0.01%	858

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fulcrum Asset Management's PRCT Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 106 shares worth $2.39K. The stake represents ﹤0.01% of the portfolio and ranks #858 among its holdings.

254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Fulcrum Asset Management held 106 shares of Procept Biorobotics worth $2.39K as of Q2 2026.
Procept Biorobotics was a new Fulcrum Asset Management position in Q2 2026.
Procept Biorobotics made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #858 holding.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.